Anti-tumor activity and tolerability of the SHP2 inhibitor RMC-4630 as a single agent in patients with RAS-addicted solid cancers

Koczywas M, Haura E, Janne P, Pacheco J, Ulahannan S, Wang JS, Burris H, Riess JW, McCoach C, Gordon M, Capasso A, Dua R, Wang Z, Chen A, Hayes J, Yang L, Masciari S, Wang X, Ou SI